|
Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Clinical research trials and Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.. Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.  Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.
Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.
For Condition: Sarcoma, Kaposi,HIV Infections
Status: Completed
Sponsor(s): Clinical Solutions ,
Synopsis: To determine the objective tumor response and remission rate of AIDS-related Kaposi's sarcomas (KS) following a single dose of tin ethyl etiopurpurin (SnET2) followed by photodynamic therapy (PDT). To determine the systemic and local toxicity, and morbidity safety profile of SnET2-PDT.
Details: All patients receive a single dose of SnET2 and are randomized to receive either PDT light treatment or no light treatment (control group). Patients are assessed prior to and at 4, 12 and 24 weeks following treatment, and are followed for 7 months.
Eligibility:
Study Type: Interventional, Treatment, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Documentation of at least one biopsy-confirmed KS lesion. - A minimum of 4 and no more than 36 KS lesions. - All eligible lesions must be bidimensionally measurable, treatable by surface (non-contact) light illumination, and <= 40 mm in diameter of the longest bidimensional axis. - ACTG disease state T(0) L(0) or (1) S(0) or (1). - Life expectancy greater than 6 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Active opportunistic infection or condition except thrush or herpes simplex virus infections. - Advanced KS tumor stages including the presence of tumor associated edema or ulceration, extensive oral KS, or KS in other non-nodal viscera. - Hematopoietic dysfunction. - Coagulation dysfunction. - Hepatic dysfunction. - Renal dysfunction. - Cardiovascular dysfunction - Presence of significant coronary artery disease requiring current treatment or myocardial infarction. - Pulmonary dysfunction. - Sepsis. - Known disorder of lipoprotein metabolism or clearance. Patients with the following prior conditions are excluded: - History of allergic or hypersensitivity reactions to light, egg proteins or egg yolks, history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum. Excluded within 7 days of therapy: - Hematopoietic dysfunction. - Coagulation dysfunction. - Hepatic dysfunction. - Renal dysfunction. Excluded within 3 months of therapy: - Pulmonary dysfunction. Excluded within 6 months of therapy: - Myocardial infarction. Prior Medication: Excluded: - Intralesional chemotherapy within the past 12 weeks. - Systemic chemotherapy or investigational drugs within the past 4 weeks. Prior Treatment: Excluded within 3 months prior to therapy: - Local cryotherapy or surgery to study lesions. - Systemic or topical photodynamic therapy agents.
Total Enrollment: 78
Location and Contact Information:
Buffalo Gen Hosp / PDT Ctr
Buffalo, New York, 14203
United States
Univ of Southern California / Los Angeles
Los Angeles, California, 90033
United States
Univ of California / San Francisco / Dermatology
San Francisco, California, 94143
United States
Thompson Cancer Survival Ctr
Knoxville, Tennessee, 37916
United States
Cedars Sinai Med Ctr
Los Angeles, California, 90048
United States
Health One - Rocky Mountain Cancer Ctr
Denver, Colorado, 80218
United States
Additional Information:
Study ID Numbers: 261A;
Study Start Date:
Record last reviewed: April 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002167
Other Sarcoma, Kaposi Studies:
1. A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
2. Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
3. The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
4. A Study of AL721 in HIV-Infected Patients with Swollen Lymph Nodes
5. Antihyperlipidemic Effects of Oyster Mushrooms
Related Studies:
Other Sarcoma, Kaposi Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.
|
|
|
|
|
|
|
|
